ElNaggar AC - Search Results

1

Anticancer potential of diarylidenyl piperidone derivatives, HO-4200 and H-4318, in cisplatin resistant primary ovarian cancer.

ElNaggar AC, Saini U, Naidu S, Wanner R, Sudhakar M, Fowler J, Nagane M, Kuppusamy P, Cohn DE, Selvendiran K. ElNaggar AC, et al. Cancer Biol Ther. 2016 Oct 2;17(10):1107-1115. doi: 10.1080/15384047.2016.1210733. Cancer Biol Ther. 2016. PMID: 27415751 Free PMC article.

2

HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer.

Rath KS, Naidu SK, Lata P, Bid HK, Rivera BK, McCann GA, Tierney BJ, Elnaggar AC, Bravo V, Leone G, Houghton P, Hideg K, Kuppusamy P, Cohn DE, Selvendiran K. Rath KS, et al. Among authors: elnaggar ac. Cancer Res. 2014 Apr 15;74(8):2316-27. doi: 10.1158/0008-5472.CAN-13-2433. Epub 2014 Mar 3. Cancer Res. 2014. PMID: 24590057 Free PMC article.

3

Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center.

Liang MI, ElNaggar AC, Nekkanti S, O'Malley DM, Hade EM, Copeland LJ, Fowler JM, Salani R, Backes FJ, Cohn DE. Liang MI, et al. Among authors: elnaggar ac. Gynecol Oncol. 2015 Sep;138(3):689-93. doi: 10.1016/j.ygyno.2015.07.094. Epub 2015 Jul 26. Gynecol Oncol. 2015. PMID: 26216728

4

Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target.

Saini U, Naidu S, ElNaggar AC, Bid HK, Wallbillich JJ, Bixel K, Bolyard C, Suarez AA, Kaur B, Kuppusamy P, Hays J, Goodfellow PJ, Cohn DE, Selvendiran K. Saini U, et al. Among authors: elnaggar ac. Oncogene. 2017 Jan 12;36(2):168-181. doi: 10.1038/onc.2016.197. Epub 2016 Jun 13. Oncogene. 2017. PMID: 27292260 Free PMC article.

5

Perioperative Outcomes for Laparotomy Compared to Robotic Surgical Staging of Endometrial Cancer in the Elderly: A Retrospective Cohort.

Backes FJ, ElNaggar AC, Farrell MR, Brudie LA, Ahmad S, Salani R, Cohn DE, Holloway RW, Fowler JM, O'Malley DM. Backes FJ, et al. Among authors: elnaggar ac. Int J Gynecol Cancer. 2016 Nov;26(9):1717-1721. doi: 10.1097/IGC.0000000000000822. Int J Gynecol Cancer. 2016. PMID: 27575633

6

Recurrent low grade serous ovarian cancer in a 20 year old woman: A case from the Ohio State University College of Medicine.

Cohn DE, Backes FJ, Wallbillich JJ, Bixel K, Crafton SM, Neff R, ElNaggar AC, Smith B, Suarez AA. Cohn DE, et al. Among authors: elnaggar ac. Gynecol Oncol. 2017 Mar;144(3):451-455. doi: 10.1016/j.ygyno.2017.01.023. Epub 2017 Feb 1. Gynecol Oncol. 2017. PMID: 28161140

7

Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center.

ElNaggar AC, Hade EM, O'Malley DM, Liang MI, Copeland LJ, Fowler JM, Salani R, Backes FJ, Cohn DE. ElNaggar AC, et al. Gynecol Oncol. 2018 Dec;151(3):501-505. doi: 10.1016/j.ygyno.2018.09.014. Epub 2018 Sep 30. Gynecol Oncol. 2018. PMID: 30282591

8

Clinical outcomes in patients with COVID-19 and gynecologic cancer: A society of gynecologic oncology COVID-19 and gynecologic cancer registry study.

Glaser GE, Lara OD, Pothuri B, Grimaldi CG, Prescott LS, Mastroyannis SA, Kim S, ElNaggar AC, Torres D, Conrad LB, McGree M, Weaver A, Huh WK, Cohn DE, Yamada SD, Fader AN. Glaser GE, et al. Among authors: elnaggar ac. Gynecol Oncol. 2022 Nov;167(2):146-151. doi: 10.1016/j.ygyno.2022.09.017. Epub 2022 Sep 23. Gynecol Oncol. 2022. PMID: 36154761 Free PMC article.

9

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.

Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M, DeRosa M, ElNaggar AC, Gershenson DM, Gray HJ, Hakam A, Jain A, Johnston C, Leath CA III, Liu J, Mahdi H, Matei D, McHale M, McLean K, O'Malley DM, Penson RT, Percac-Lima S, Ratner E, Remmenga SW, Sabbatini P, Werner TL, Zsiros E, Burns JL, Engh AM. Armstrong DK, et al. Among authors: elnaggar ac. J Natl Compr Canc Netw. 2019 Aug 1;17(8):896-909. doi: 10.6004/jnccn.2019.0039. J Natl Compr Canc Netw. 2019. PMID: 31390583

10

Addition of Everolimus Post VEGFR Inhibition Treatment Failure in Advanced Sarcoma Patients Who Previously Benefited from VEGFR Inhibition: A Case Series.

ElNaggar AC, Hays JL, Chen JL. ElNaggar AC, et al. PLoS One. 2016 Jun 13;11(6):e0156985. doi: 10.1371/journal.pone.0156985. eCollection 2016. PLoS One. 2016. PMID: 27295141 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

38 results

Search Page

Filters